EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition. OnFebruary 22, 2018, Emergent announced financial and operating results for the period endedDecember 31,2017. The full text of the press release issued in connection with the announcement is attached as Exhibit 99 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
ExhibitNo. |
Description |
|
Press release issued by the company on February 22, 2018. |
Emergent BioSolutions Inc. ExhibitEX-99 2 ex99.htm EXHIBIT 99 EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS – Reaffirms full year 2018 forecast and 2020 goals – Revises 1Q 2018 forecast GAITHERSBURG,…To view the full exhibit click here
About EMERGENT BIOSOLUTIONS INC. (NYSE:EBS)
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.
